The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On March 25, LivaNova received FDA approval for its aura6000 system to treat Obstructive Sleep Apnea (OSA). The system utilizes neurostimulation technology and represents a pivotal growth step for the company. The approval was granted based on strong results from clinical trials.